Prognostic Value of the Triglyceride-Glucose (TyG) Index for Renal Function Progression in Patients with CKD Stages 3–4

Why It Matters

Identifying a low‑cost, readily available biomarker like the TyG index enables clinicians to pinpoint CKD patients at heightened risk of rapid decline, informing more aggressive metabolic or nutritional interventions.

Key Takeaways

• TyG index predicts CKD stage 3‑4 progression risk
• Each 1‑unit rise in TyG raises hazard by 10%
• Highest TyG quartile (Q4) shows 17% higher progression risk
• U‑shaped curve: lowest risk at TyG 8.6‑8.8
• TyG is inexpensive, readily available for early CKD risk stratification

Pulse Analysis

Chronic kidney disease remains a leading cause of morbidity worldwide, and patients in stages 3‑4 sit at a therapeutic crossroads where slowing progression can dramatically improve outcomes. Traditional measures of insulin resistance, such as the hyperinsulinemic‑euglycemic clamp, are impractical for routine use, prompting researchers to seek surrogate markers. The triglyceride‑glucose (TyG) index, derived from fasting triglyceride and glucose levels, offers a cost‑effective proxy for metabolic dysfunction and has been linked to cardiovascular risk, but its prognostic value for CKD progression had been unclear until this large Chinese cohort provided robust evidence.

The study’s multivariate models demonstrated that a modest rise in the TyG index translates into a measurable increase in renal decline risk, with the highest quartile experiencing a 17% greater hazard of reaching end‑stage outcomes. Notably, the relationship was not linear; a U‑shaped curve indicated that both excessively high and unusually low TyG values correlate with adverse kidney trajectories. High TyG likely reflects severe insulin resistance, driving glomerular hyperfiltration, inflammation, and lipotoxic injury. Conversely, very low TyG may signal malnutrition‑inflammation‑wasting, a known accelerator of CKD progression. This nuanced insight underscores the need for clinicians to interpret TyG values within a broader clinical context rather than applying a single cutoff.

From a practice standpoint, incorporating the TyG index into CKD management algorithms could enable earlier identification of patients who would benefit from targeted interventions—such as lifestyle modification, optimized glycemic control, or lipid‑lowering therapy—to mitigate insulin resistance. The index’s simplicity means it can be calculated from standard laboratory panels without additional cost, facilitating widespread adoption. However, the retrospective design, single‑baseline measurement, and predominance of Chinese participants warrant caution; prospective, multi‑ethnic studies are needed to confirm generalizability and to explore whether dynamic changes in TyG over time improve predictive accuracy. Nonetheless, the evidence positions TyG as a promising tool for refining risk stratification and personalizing care in CKD stages 3‑4.